Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 29 Aug 2026

Lu-177 PSMA Therapy Does Not Work for Everyone

Lutetium Lu-177 PSMA therapy can extend survival in men with PSMA-positive mCRPC - but response is not guaranteed for everyone. This article looks at real VISION trial data, the reasons some patients do not respond, and what to discuss with your oncologist before you start.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 29 Aug 2026
Lu-177 PSMA Therapy Does Not Work for Everyone

This article covers lutetium Lu-177 vipivotide tetraxetan (commonly known as Pluvicto or Lu-177 PSMA therapy) for men with metastatic castration-resistant prostate cancer (mCRPC). If you have tried hormone therapies and chemotherapy and want to know if this treatment is right for you, this article is for you.

The short answer is: it may help, but not everyone responds the same way. About half of men in the VISION trial didn't achieve a 50% or greater PSA drop. This doesn't mean it's wrong to try the therapy, but talking openly with your oncologist before you start is crucial.

What Does Response Mean in Lu-177 PSMA Therapy?

Researchers track response to lutetium PSMA therapy in three main ways.

  • PSA50 response: a drop in PSA (prostate-specific antigen) of 50% or more from your starting level. This is the most commonly reported marker in clinical trials.
  • Imaging response: whether scans show stable, shrinking, or growing disease - measured as radiographic progression-free survival (rPFS), the time before cancer visibly grows on a scan.
  • Overall survival (OS): whether patients live longer than those receiving standard care alone.

These markers don't always move together. PSA can fall while disease progresses on scans, or scans can look stable while PSA rises. Your oncologist should explain which markers matter most for your case and how they will track each one during your treatment cycles.

How Many Patients Actually Respond?

The clearest picture comes from the VISION trial - the phase 3 international study that led to FDA approval of Pluvicto in March 2022. The trial included men with PSMA-positive mCRPC who had already received at least one androgen receptor pathway inhibitor and one or two taxane chemotherapy regimens.

The main result: median overall survival was 15.3 months with lutetium therapy plus standard care, compared with 11.3 months for standard care alone - a hazard ratio of 0.62, roughly a 38% relative reduction in the risk of death. This was statistically significant and clinically meaningful, as reported in the VISION trial published in the New England Journal of Medicine in 2021.

But the PSA response data shows a more complete picture. About 46% of men in the VISION trial achieved a PSA50 response - a 50% or greater PSA drop. More than half did not reach that threshold. Radiographic progression-free survival improved significantly (8.7 months versus 3.4 months in the control group), but many patients still progressed quickly on imaging. The FDA approval summary for Pluvicto confirms these results as the basis for approval.

This doesn't rule out trying the therapy. Even patients who don't achieve a PSA50 response may see some disease stabilization. And the overall survival benefit held across the trial group as a whole. But realistic expectations matter - both for deciding whether to start and for how you read early results once you do.

Why Do Some Patients Not Respond?

Non-response isn't simply bad luck. Several biological and clinical factors appear to reduce the chance of real benefit from lutetium PSMA therapy.

PSMA heterogeneity within the cancer

PSMA (prostate-specific membrane antigen) is the target that lutetium therapy binds to. The drug attaches to PSMA on cancer cell surfaces and delivers targeted radiation. But prostate cancers vary. Different metastatic lesions in the same person can have very different PSMA expression levels. When some tumors have high PSMA and others have little or none, the drug may control PSMA-positive sites while PSMA-low sites continue to grow. PSMA heterogeneity is one of the main reasons for incomplete response, as shown in published research on determinants of outcome in lutetium PSMA therapy.

PSMA-negative, FDG-positive lesions

Some lesions show up on FDG-PET scans (detecting metabolic activity) but not on PSMA-PET scans. These lesions are active and growing but express little PSMA, so lutetium can't target them effectively. In the VISION trial, patients with PSMA-negative lesions above a certain size were excluded because the drug wouldn't work well for them. If your cancer includes many PSMA-low lesions, your overall response is likely to be partial at best.

Neuroendocrine differentiation

After multiple treatments, some prostate cancers can change. A small but important subset shifts toward a neuroendocrine phenotype - sometimes called treatment-emergent neuroendocrine prostate cancer (t-NEPC). These cells tend to lose PSMA expression. If this change has occurred, lutetium PSMA therapy may not reach most of your disease. Molecular testing alongside combined PSMA-PET and FDG-PET imaging can sometimes detect this shift.

Liver metastases and high-burden visceral disease

Men with liver metastases or extensive spread to internal organs tend to have worse outcomes with lutetium PSMA therapy. Liver involvement often shows that the cancer has overcome multiple prior treatment lines. This doesn't automatically rule out lutetium therapy, but it changes the risk-benefit balance and makes talking with your oncologist especially important.

Prior treatment burden and bone marrow reserve

By the time most patients reach lutetium therapy, their bone marrow has often taken damage from prior chemotherapy or radiation. Lutetium PSMA therapy adds further bone marrow suppression as a side effect. Patients who begin with already-low blood counts may not be able to complete all planned cycles, which limits total radiation dose and may reduce the chance of real benefit. Your team should explain the blood count thresholds they use to pause or stop treatment.

What Makes a Patient Ineligible from the Start?

Some patients are not suitable candidates before treatment even begins. Understanding these criteria helps you make sense of what your PSMA-PET scan is actually measuring.

Low or absent PSMA on imaging. If your PSMA-PET scan doesn't show enough tracer activity across your metastatic lesions, lutetium therapy has no reliable target. The VISION trial used specific PSMA-positivity thresholds for inclusion. Borderline results require careful specialist review. To understand what your scan means for eligibility, see What Your PSMA-PET Results Mean for Lu-177 Eligibility.

Impaired kidney function. Lutetium leaves your body through your kidneys, which also express PSMA, so your kidneys get radiation during each cycle. Patients with very low kidney function may face too much risk of further damage. Exact thresholds vary by center, but a glomerular filtration rate (GFR) below 40 mL/min is often considered unsafe. Your team assesses kidney function before every cycle, not just at baseline.

Very low baseline blood counts. Very low platelets, white blood cells, or red blood cells at the start of treatment may make it unsafe to proceed with a therapy that adds further marrow suppression.

Very poor performance status. Most clinical programs require patients to do at least light self-care (roughly ECOG performance status 0 to 2). In patients who are mostly bedbound (ECOG 3 or 4), the likely benefit is less certain and the risk of harm is higher.

Early Signals That Treatment May Not Be Working

Once you start lutetium PSMA therapy, your team should watch for specific signals about whether your cancer is responding - and you should too.

The first thing to understand is PSA flare - a temporary rise in PSA in the first few weeks after your first cycle. PSA flare is common and doesn't by itself mean treatment is failing. It often happens because dying cancer cells release PSA into your bloodstream as they break down. It can be alarming, but it's a recognized pattern in radioligand therapy.

The more concerning signal is a PSA that keeps rising across two or more cycles without any plateau or decline. Patients who show consistent PSA progression after the first cycle typically have a much lower chance of benefit from continuing therapy. This is why most experienced centers re-evaluate with imaging and PSA trends after cycles two and three before going ahead with the full four-to-six cycle course. For a detailed breakdown of what different PSA patterns mean during treatment, see Reading PSA Trends During Lu-177 PSMA Therapy.

What to Ask Your Oncologist Before You Start

Before beginning lutetium PSMA therapy, have a clear conversation with your oncologist or nuclear medicine specialist to understand your realistic chance of benefit and what happens if the therapy doesn't work. Here are five questions to ask:

  • What is my PSMA-PET result, and how does my PSMA uptake compare to the threshold used in the VISION trial?
  • Do any of my lesions appear PSMA-negative on imaging - and if so, how many and how large?
  • What are my current kidney function numbers, and how close are they to the threshold where treatment becomes unsafe?
  • What will you monitor during treatment to determine whether I am responding?
  • If lutetium PSMA therapy doesn't work, what is the next step for my care?

That fifth question is as important as any other. Patients who don't respond - or who respond initially and then progress - may still have good options available. Understanding what comes next before you start helps you plan rather than react. For full details, see Lu-177 PSMA Resistance and Next Steps for mCRPC.

If you are traveling internationally for lutetium PSMA therapy - particularly from a country where the treatment isn't locally available - getting a pre-travel eligibility assessment is a good idea. You can request a Lu-177 eligibility review through Art of Healing Cancer before committing to travel or a treatment program. The review can clarify your realistic chance of response and identify what alternative options exist if your PSMA expression doesn't meet the threshold.

Men with mCRPC often take long-term androgen deprivation therapy, which can thin bones alongside existing bone metastases. Bone and joint support is available, including supplements from Ayurnomics. Always discuss any supplement with your oncology team before adding it to your regimen.

When to Talk to Your Doctor

Speak with your oncologist or nuclear medicine team before starting lutetium PSMA therapy if your PSMA-PET results showed low or mixed uptake, if you have liver metastases or other signs of visceral involvement, or if your kidney function has been declining. Ask these questions at the start - not after your first cycle. If you are already in treatment and your PSA hasn't responded after two cycles, ask your team specifically what the imaging shows and what the plan is for continuing or changing therapy.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What percentage of patients respond to Lu-177 PSMA therapy?

In the VISION trial, approximately 46% of patients achieved a PSA50 response - a drop of 50% or more in PSA. More than half of treated patients did not reach that specific threshold. Radiographic progression-free survival improved significantly compared with standard care (8.7 months versus 3.4 months), and overall survival improved by a median of about four months. Response rates vary depending on factors such as PSMA expression level, disease burden, and prior treatment history.

Can I still receive Lu-177 PSMA therapy if my PSMA-PET scan shows mixed results?

It depends on the specific findings. The VISION trial excluded patients with PSMA-negative lesions above certain size thresholds. If your scan shows some PSMA-positive lesions alongside some PSMA-negative ones, your eligibility depends on the size and number of those PSMA-negative sites. A nuclear medicine specialist or theranostics team should review your actual scan images and compare them against current eligibility standards before a decision is made.

What happens if Lu-177 PSMA therapy does not produce a response?

If lutetium therapy does not produce a response, or stops working after an initial response, other options may still be available. These could include alternative chemotherapy regimens, PARP inhibitors for patients with certain DNA repair mutations such as BRCA1 or BRCA2 changes, other targeted therapies, or clinical trials. Your oncologist should discuss next-line options with you before you start lutetium therapy - not only after it fails to respond.

How soon can I tell if Lu-177 PSMA therapy is working?

Most centers evaluate response formally after two to three cycles, roughly 12 to 18 weeks into treatment. PSA may temporarily rise in the first few weeks after the first cycle - this is called a PSA flare and does not necessarily indicate treatment failure. A PSA that continues to rise across multiple cycles without any stabilization is a more concerning pattern and should prompt a direct conversation with your oncologist about whether to continue.

Why does my oncologist require a PSMA-PET scan before starting treatment?

The PSMA-PET scan is the eligibility checkpoint for lutetium PSMA therapy. It shows whether your cancer expresses enough PSMA for the therapy to have a reliable target. Without sufficient PSMA expression across your metastatic lesions, the drug has little to bind to and is unlikely to reach most of your cancer effectively. The scan also helps identify any PSMA-negative lesions that might continue to grow even if other lesions respond to treatment.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA: Real Response Rates Before You Start | lutetium-therapy